Autonomous B-cell receptor signaling and genetic aberrations in chronic lymphocytic leukemia-phenotype monoclonal B lymphocytosis in siblings of patients with chronic lymphocytic leukemia.


Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
13 Jul 2023
Historique:
received: 01 03 2023
medline: 13 7 2023
pubmed: 13 7 2023
entrez: 13 7 2023
Statut: aheadofprint

Résumé

Clonal expansion of CD5-expressing B cells, commonly designated as monoclonal B lymphocytosis (MBL), is a precursor condition for chronic lymphocytic leukemia (CLL). The mechanisms driving subclinical MBL B-cell expansion and progression to CLL, occurring in app. 1% of affected individuals, are unknown. An autonomously signaling B-cell receptor (BCR) is essential for CLL pathogenesis. The objective of this study was functional characterization of the BCR of MBL in siblings of CLL patients and comparison of genetic variants in MBL-CLL siblings pairs. Screening of peripheral blood by flow cytometry detected 0.2-480 clonal CLL-phenotype cells per μL (median: 37/μL) in 34 of 191 (17.8%) siblings of CLL patients. Clonal BCR isolated from highly purified CLL-phenotype cells induced robust calcium mobilization in BCR-deficient murine pre-B cells in the absence of external antigen and without experimental cross-linking. This autonomous BCR signal was less intense than the signal originating from CLL BCR of their CLL sibling. According to genotyping by single nucleotide polymorphism array, whole exome, and targeted panel sequencing, CLL risk alleles were found with high and similar prevalence in CLL patients and MBL siblings. Likewise, the prevalence of recurrent CLL-associated genetic variants was similar between CLL and matched MBL samples. However, copy number variations and small variants were frequently subclonal in MBL cells, suggesting their acquisition during subclinical clonal expansion. These findings support a stepwise CLL pathogenetic model wherein autonomous BCR signaling leads to a non-malignant (oligo)clonal expansion of CD5+ B cells, followed by malignant progression to CLL after acquisition of pathogenic genetic variants.

Identifiants

pubmed: 37439337
doi: 10.3324/haematol.2022.282542
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Edwin Quinten (E)

Department of Hematology, Leiden University Medical Center, Leiden.

Julieta H Sepúlveda-Yáñez (JH)

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands; School of Medicine, Universidad de Magallanes, Punta Arenas, Chile.

Marvyn T Koning (MT)

Department of Hematology, Leiden University Medical Center, Leiden.

Janneke A Eken (JA)

Department of Hematology, Leiden University Medical Center, Leiden.

Dietmar Pfeifer (D)

Department of Medicine I, University Medical Center Freiburg, Freiburg.

Valeri Nteleah (V)

Department of Hematology, Leiden University Medical Center, Leiden.

Ruben A L De Groen (RAL)

Department of Hematology, Leiden University Medical Center, Leiden.

Diego Alvarez Saravia (DA)

School of Medicine, Universidad de Magallanes, Punta Arenas, Chile.

Jeroen Knijnenburg (J)

Department of Clinical Genetics, Leiden University Medical Center, Leiden.

Hedwig E Stuivenberg-Bleijswijk (HE)

Department of Hematology, Leiden University Medical Center, Leiden.

Milena Pantic (M)

Department of Medicine I, University Medical Center Freiburg, Freiburg.

Andreas Agathangelidis (A)

Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece; Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.

Andrea Keppler-Hafkemeyer (A)

Department of Medicine I, University Medical Center Freiburg, Freiburg.

Cornelis A M Van Bergen (CAM)

Department of Hematology, Leiden University Medical Center, Leiden.

Roberto Uribe-Paredes (R)

Department of Computer Engineering, Universidad de Magallanes, Punta Arenas, Chile; Centre for Biotechnology and Bioengineering, Santiago, Chile.

Kostas Stamatopoulos (K)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm.

Joost S P Vermaat (JSP)

Department of Hematology, Leiden University Medical Center, Leiden.

Katja Zirlik (K)

Department of Medicine I, University Medical Center Freiburg, Freiburg, Germany; Tumor-und Brustzentrum Ostschweiz, Chur.

Marcelo A Navarrete (MA)

School of Medicine, Universidad de Magallanes, Punta Arenas, Chile.

Hassan Jumaa (H)

Institute of Immunology, University of Ulm, Ulm.

Hendrik Veelken (H)

Department of Hematology, Leiden University Medical Center, Leiden. j.h.veelken@lumc.nl.

Classifications MeSH